eMedicine Specialties > Neurology > Pediatric Neurology

Benign Neonatal Convulsions

Nancy Theresa Rodgers-Neame, MD, Assistant Professor, Department of Molecular Pharmacology and Physiology, University of South Florida; Director, Florida Comprehensive Epilepsy and Seizure Disorders Program

Updated: Apr 8, 2009

Introduction

Background

Benign neonatal convulsions are defined as seizures with onset after birth through day 28 in an otherwise healthy child with no other known medical or neurological problems. Such cases may be familial or isolated. Psychomotor development should be normal for a full-term or near full-term infant with benign convulsions. Between seizures, findings on neurologic examination should be normal. Clinically, the seizures are frequent and brief, occasionally occurring many times within a day. The brief seizures are followed by a short or no postictal state. The episodes usually resolve within days but may continue for several months and have no neurological sequelae.

The occurrence of status epilepticus is common in benign idiopathic neonatal convulsions (BINC) but is uncommon in benign familial neonatal convulsions (BFNC). Because benign idiopathic neonatal convulsions is a diagnosis of exclusion, it is nearly always made in retrospect, when the seizures spontaneously resolve and the infant is found to have neurologically normal development.^1,2,3,4

At the outset, considering how broadly to define benign neonatal convulsions is important: for example, whether to include those with myoclonic or partial onset components or those with a known or treatable etiology. Certainly, multiple presentations of seizures that may have a benign long-term outcome are possible in the neonatal period.^3,7 Definite advantages exist in approaching the subject from each position. Too broad of a definition in a research situation can lead to confusion when searching for a common pathology. Too narrow of a definition in the clinical setting may result in confusion about a clinical diagnosis. Later, when the mechanisms are more well defined, broader groups not meeting the initial criteria may exist.

Clinically, the more important considerations are taking an appropriate approach to the patient and family, making the correct diagnosis, and pursuing treatment options concordant with the situation. Sometimes, the correct clinical plan may include a decision not to treat a benign condition with medications that often are not so benign. It should also be emphasized that a definitive diagnosis may take some time, given the often retrospective nature of the diagnosis.

Pathophysiology

The genetics of benign familial neonatal convulsions is currently an area of active investigation. Inheritance is autosomal dominant. Loci on chromosome arm 20q have been identified for most families. At least one family was identified to have a locus on chromosome arm 8q. Some of these loci have been identified further as specific mutations in the KCNQ2 and KCNQ3 M-type potassium channel proteins.^{8,9,10,11,12,36,37,38} The specific location of the mutation appears to vary from family to family and at least 1 family has been noted to include an increased incidence of rolandic epilepsy.⁵

Several additional genes have been associated with benign familial neonatal convulsions in single families, including KCNQ5 M-type potassium channel in one family.¹³ Another family has been noted to have abnormalities in the acetylcholine alpha-4 receptor subunit, which also has been associated with autosomal dominant nocturnal frontal lobe epilepsy.^14,15

Expression of the mutated genes in xenopus oocytes has provided some insight into how the potassium channel mutation leads to lowering of the seizure threshold. The potassium current was reduced in the channel expressed by the mutated gene to 5% of that in the channel expressed by the normal gene. However, voltage sensitivity and kinetics were not affected. The effect is therefore to impair repolarization of the neuronal cell membrane, leading to hyperexcitability of the central nervous system.^16,17

Given the severity of the impairment to the M-type potassium channel, that these seizures are difficult to treat is not surprising, since no currently used antiepileptic medications are known to increase the efficiency of the potassium channel. What is surprising is the self-remitting nature of the condition, that many individuals never have another seizure, and that the profound abnormalities of the voltage-gated potassium channel do not appear to compromise the nervous system in any other way. Possibly, some intrinsic method exists for up-regulating expression of the normal potassium channel genes, or the neurons may find other ways of normalizing the hyperexcitability, but these theories remain to be demonstrated.^18,19,20

A number of cases have been reported where benign idiopathic or familial neonatal convulsions have preceded the development of epilepsy later in life. Similarly, perhaps, febrile seizures early in life may predispose to later development of epilepsy. Given the polygenic etiology of susceptibility to epilepsy, it is not surprising that an abnormality in part of the system maintaining homeostasis within the neuron should render the neuron more prone to dysfunction.^21,22,23,24

A complicating factor is that in neonates the action of the GABA-A receptor is excitatory rather than inhibitory in the brain.^25,26,27,28

The pathophysiology of BINC has been less well defined and remains somewhat elusive. One issue is that the neonatal brain is more prone to seizures, which has been demonstrated in a number of experimental systems.^25,26,27,28

Several etiologies have been proposed as a result of isolated findings of lowered zinc level in the cerebrospinal fluid and low levels of vitamin B-6.²⁹ Both of these compounds are important cofactors in ligand-gated ion channel function. However, these findings have not been robust, and the search continues. These seizures are likely also linked in some way to ion channel dysfunction as is found in the familial seizures, but they may be caused by multiple etiologies or occur as a multigenomic entity.^30,31,32 These sorts of multifactorial etiologies are more difficult to define precisely. More research is needed in this area, and apparent monogenic diseases, such as benign familial neonatal convulsions, provide important insight into more complex etiologies.

Frequency

United States

Benign neonatal convulsions in the United States are uncommon, ie, not rare but not common, either. Underreporting is likely an issue. Seizures that resolve in the early months of life without sequelae and normal neonatal development are often lost to follow up. Exact frequencies are undetermined. Families identified with the familial form thus far have been primarily of western European origin, although one report from Japan exists.^33,34 Part of the reason for this is likely the stability of reporting resources in European countries.

International

Benign neonatal convulsions also are uncommon internationally. Families identified with the familial form thus far have been primarily of western European or Japanese origin.^33,34 This is certainly an artifact of observation rather than occurrence.

Mortality/Morbidity

The risk of seizures later in life is 11-16% in benign familial neonatal convulsions and somewhat less in benign idiopathic neonatal convulsions, perhaps as low as 2%. Other reported problems have been sporadic and within the incidence range expected for the general population.²⁹

Race

All cases to date have been reported in families of European or Japanese origin.^33,34

Sex

In benign familial neonatal convulsions, the frequency in males is equal to that in females, compatible with simple autosomal dominant inheritance.²⁹

In benign idiopathic neonatal convulsions, males are affected somewhat more frequently than females (62%) in examined cases (N=199).²⁹ With such a small number of cases reported, this may be due to reporting bias or simple sampling error, or it may represent a real difference in frequency.

Age

• In benign idiopathic neonatal convulsions, patients are aged 1-7 days at onset, with day 5 the most frequently reported day of onset. The frequent onset on the fifth day of life is responsible for the term fifth day disease or fifth day fits, which continues to be used in the pediatric literature. However, in actuality, fifth day fits are most likely seizures that were reportedly linked to the use of hexachlorophene (pHisoHex), which now has been discontinued.³⁵
• Patients may be slightly older at onset in benign familial neonatal convulsions, with some patients in previously identified families several weeks old. Characteristically, the onset of benign familial neonatal convulsions occurs when neonates are aged 2 days.^1,2,4
• Interestingly, unaffected family members of patients with benign familial neonatal convulsions have a higher-than-expected risk of developing epilepsy in later life. Presently, family studies have not clarified whether these relatives always share the genetic defect in the potassium channel.^3,29

Clinical

History

• The history should be free of suspicion of causative elements for neonatal seizures.
  • Such elements include prenatal or perinatal stroke, perinatal asphyxia, fever, persistent lethargy, pertinent maternal illness or drug abuse, signs of metabolic dysfunction, or neurological abnormalities.
  • Other criteria that have been noted but may be of limited value are a lack of neurological or genetic abnormalities in siblings or other family members or metabolic dysfunction of any cause. A 5-minute Apgar score less than 9 also has been suggested but is almost certainly too stringent to require for diagnosis.
• Diagnostic criteria have been suggested by Miles and Holmes²⁹ as well as Plouin³ for both benign familial neonatal convulsions and benign idiopathic neonatal convulsions.
  • Diagnostic criteria - Benign idiopathic neonatal convulsions^3,29
    • Infants born after 39 weeks' gestation
    • Apgar score of 9 or more at 5 minutes (lower scores should not exclude the diagnosis if other criteria are met)
    • Presence of a seizure-free interval between birth and the onset of seizures
    • Clonic and/or apneic seizures
    • Negative findings on evaluation for alternative etiology
    • Normal developmental and intellectual outcome (largely determined in retrospect)
    • Lack of seizures beyond the neonatal period
  • Diagnostic criteria - Benign familial neonatal convulsions^3,29
    • Normal neurologic examination findings
    • Negative findings on evaluation for alternative etiology
    • Normal developmental and intellectual outcome (retrospective criteria)
    • Positive family history of newborn or infantile seizures
    • Onset of seizures during neonatal period or early infancy

Physical

Physical and neurologic examination findings should be normal during the interictal period.

Causes

• Several causes have been proposed for benign idiopathic neonatal convulsions, including rotavirus infection, low CNS zinc levels, and vitamin B-12 deficiency. None of these causes has been confirmed. The more likely explanation is the presence of a self-limited malfunction in one of the ligand-gated or voltage-gated ion channels.³
• Most families in which benign familial neonatal convulsions occurs have abnormalities in the genes coding for the KCNQ2 and KCNQ3 potassium channels.^39,40
  • This defect leads to abnormal repolarization of the neuronal membrane and likely causes the neonatal seizures.
  • The real puzzle is why this profound abnormality in membrane polarization does not lead to more problems in later life or persistent seizures extending from the neonatal period. This may be evidence that the drive toward homeostasis in the brain is strong, with redundant systems capable of maintaining a seizure-free state until more than one system is affected, or that systems are affected that do not have the redundancy of the voltage-gated potassium channels. Moreover, the normal potassium channels may be up-regulated to accommodate for the deficiency in function of the abnormal channels.
  • Clearly, the immature infant brain is different electrophysiologically during early development. GABA has a seemingly paradoxical excitatory effect.²⁵ Glutamate synapses are slow to develop, and there is delayed expression of the K⁺/Cl^- cotransporter KCC2 and NKCC1.²⁶ The primary inhibition in the neonatal brain is presynaptic rather than postsynaptic. As the brain matures and expression of postsynaptic inhibitory and excitatory processes develop, the maintenance of neuronal homeostasis as well as postsynaptic EPSPs and IPSPs gradually approach the adult state. Since all of these processes are under development at the same time as neonatal convulsions appear, it is likely that neonatal seizures are affected by the normal developmental sequence of the other neurotransmitter systems.

Differential Diagnoses

Other Problems to Be Considered

Vitamin B-6 deficiency
Maternal drug abuse

Workup

Laboratory Studies

• The reason for ordering tests in benign familial and idiopathic neonatal convulsions is to exclude the presence of any etiology for the seizures. The diagnosis of benign infantile convulsions of either type requires that no other explanation exist for the seizures. Order tests for individual patients with a plan for that patient in mind. While a "shotgun" approach is wasteful and unreasonable, it is also important not to miss a diagnosis of a treatable meningoencephalitis in the early stages or intracranial hemorrhage. Both of these conditions in neonates lack the typical findings observed in older infants and children, and the only early symptom may be seizures. Also entertain a healthy suspicion for child abuse in neonates, who often have just arrived home from the hospital following delivery. Review of basic screening laboratory studies performed at delivery may also be helpful.
  • Chemistries - Basic metabolic panel plus calcium, magnesium, phosphorus, thyroid function tests, and possibly B vitamin levels
  • Basic hematologic labs - CBC, prothrombin time, activated partial thromboplastin time
  • Lumbar puncture - Cerebrospinal fluid examination to exclude neonatal meningoencephalitis or occult blood
• Any abnormalities found that are inconsistent with a diagnosis of benign neonatal convulsions require the appropriate further workup and treatment.

Imaging Studies

• MRI or CT scan of the brain
  • Perform one or both of these tests in every patient with neonatal seizures to exclude structural lesions and intracranial hemorrhage.
  • An argument can be made that both are needed since CT scan yields better information on acute hemorrhage and skull fracture, and MRI shows better brain structural detail.

Other Tests

• Electroencephalography
  • The classic EEG observed in 60% of patients with BINC is a rolandic discharge in the theta range that is alternating or discontinuous with intermixed sharp activity. Interhemispheric asymmetry is observed frequently; it is unresponsive to stimulation of any kind. This pattern often is termed theta pointu altérnant.^3,7,29
  • The remaining patients with benign idiopathic neonatal convulsions have either a normal interictal EEG or focal abnormalities. The EEG during seizures is most often high-voltage (200-400 µV) generalized discharges, which may appear to have a focal onset.
• In benign familial neonatal convulsions, the interictal EEG is most commonly normal (50-70% of patients). The theta pointu altérnant pattern also is observed but only in approximately 25% of patients. In a small percentage of patients, focal, often rolandic, discharges or spikes may be present.^41,42,3
• In selected patients, continuous video-EEG can be used to confirm behavioral events concordant with abnormal EEG and to confirm that treatment is effective. The state of the patient and improvement or deterioration can make decision-making easier and facilitate accurate communication with an often anxious family.⁷

Treatment

Medical Care

Although the seizures are benign, general agreement exists that they should be treated, particularly benign idiopathic neonatal convulsions.

• Treatment with antiepileptic medications may prevent the occurrence or reduce the length of the period of status epilepticus. Continuing antiepileptic treatment for more than 10 days may not be necessary in benign idiopathic neonatal convulsions. One thing that should be kept in mind with treatment is that while seizures may abate the EEG may remain abnormal. In some cases, the EEG may change appearance but remain abnormal nevertheless.
• The medications used most frequently are benzodiazepines, phenobarbital, and fosphenytoin, but no particular reason exists for the preferential use of these drugs rather than some of the newer drugs, except for their current availability in intravenous formulations and the long-term experience with their use in neonates.  GABA-A agonists (barbiturates and benzodiazepines) should be used with caution in the neonate.
• When IV and liquid formulations become available, some of the newer drugs may prove to be of greater benefit in the future owing to their multiple mechanisms of action and their neuromodulatory/neuroprotective effects.
• The disadvantages of phenobarbital and benzodiazepines are that they are overdosed easily in the neonate and can be very sedating. In addition, ample evidence shows that GABA-A agonists may not be a good choice in the immature brain. 
• Fosphenytoin may be used acutely, but phenytoin is absorbed unpredictably in the neonate and should not be used as an oral preparation.
• Use caution when treating status epilepticus with phenobarbital in neonates. Mistaking a normal deep anesthesia EEG in this age group with a burst suppression pattern of status epilepticus is easy.
• Do not treat neonates in whom benign convulsions are suspected with valproate because of increased risk of liver failure with the drug and the benign nature of the syndrome.

Medication

No specific antiepileptic medication is preferred for the treatment of benign neonatal convulsions. In general, most epileptologists agree that status epilepticus should be treated when it occurs. Most neonates are best treated at this time with phenobarbital because of long experience with the drug, convenient monitoring, and adequate IV and PO absorption in the neonate. However, treatment has not been shown unequivocally to have an effect except possibly to decrease the duration or severity of the seizures. By definition, the seizures resolve in days (benign idiopathic neonatal convulsions) to weeks (benign familial neonatal convulsions).

Limit the choice of antiepileptic drug to those with no serious potential adverse effects. Most notably, avoid valproate in this age group if benign convulsions are suspected, since neonates are at the highest risk for liver failure due to valproate. Avoid phenytoin because of cardiac adverse effects, the high possibility of extravasation in neonates, and problems with reliable absorption if administered PO. A trial off the antiepileptic drug(s) should begin soon after the seizures stop and the EEG is normal.

An important factor to remember when treating neonates is that pharmacokinetics and pharmacodynamics are very different than in infants. Do not use infant loading dosages, since they may lead quickly to toxic levels that resolve slowly.

Neonatal pharmacology is complex. Maturation of general liver and renal function is in a period of transition from the fetal to infant state. Stresses or lack of stress on the systems in utero greatly affect the function and maturation of both systems.

Normal glomerular filtration rate (GFR) in the neonate varies in individuals from 1-4 mL/min and can increase rapidly as maturation of the renal cortex progresses. Adult values for GFR are not reached before the infant is aged 2.5-5 months.

Blood flow within the hepatic portal system changes at birth with closing of the ductus venosus. Maturation of the glucuronidation pathway often is slowed. Neonates whose mothers have been exposed to drugs (both prescribed and otherwise) may have active cytochrome P-450 enzymes, and unexposed neonates have initial low activities that usually increase rapidly with the introduction of drugs such as phenobarbital.

Anticonvulsants

These agents prevent seizure recurrence and terminate clinical and electrical seizure activity.

Phenobarbital (Barbita, Luminal, Solfoton)

DOC for treatment of neonatal seizures. Use care in dosing since toxicity can occur quickly and resolve slowly. Also doses that are initially adequate may need to be increased quickly as cytochrome P-450 becomes more active.

Dosing

Adult

Pediatric

20 mg/kg loading dose IV and 5 mg/kg/day maintenance dosing; take care when administering to neonates whose drug biotransformation and excretion may be reduced at birth due to immaturity of glucuronidation pathway, cytochrome P-450 system, and reduced GFRs

Interactions

May decrease effects of chloramphenicol, digitoxin, corticosteroids, carbamazepine, theophylline, verapamil, metronidazole, and anticoagulants (patients stabilized on anticoagulants may require dosage adjustments if added to or withdrawn from their regimen); alcohol may produce additive CNS effects and death; chloramphenicol, valproic acid, and MAOIs may increase toxicity; rifampin may decrease effects

Contraindications

Documented hypersensitivity; severe respiratory disease; marked impairment of liver function; nephritis

Precautions

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

In prolonged therapy, evaluate hematopoietic, renal, hepatic, and other organ systems; caution in fever, hyperthyroidism, diabetes mellitus, and severe anemia since adverse reactions can occur; caution in myasthenia gravis and myxedema

Fosphenytoin (Cerebyx)

Initially may be used to control status epilepticus in patients with benign neonatal convulsions; however, unsuitable for long-term therapy.

Dosing

Adult

Pediatric

Initial loading dose: 15-20 phenytoin equivalents per kg IV; maintenance should be guided by clinical response and free drug levels and may be as low as 1.5 mg/kg/d in divided doses; in older children, enteral dosing of phenytoin is typically 5 mg/kg/day, or in infants up to 10 mg/kg/day or higher

Interactions

Amiodarone, benzodiazepines, chloramphenicol, cimetidine, disulfiram, ethanol (acute ingestion), omeprazole, phenacemide, phenylbutazone, succinimides, fluconazole, isoniazid, metronidazole, miconazole, sulfonamides, trimethoprim, and valproic acid may increase toxicity
Barbiturates, carbamazepine, theophylline, diazoxide, ethanol (chronic ingestion), rifampin, antacids, charcoal, and sucralfate may decrease effects
May decrease effects of acetaminophen, corticosteroids, dicumarol, disopyramide, doxycycline, estrogens, haloperidol, amiodarone, carbamazepine, cardiac glycosides, methadone, metyrapone, mexiletine, oral contraceptives, quinidine, theophylline, valproic acid

Contraindications

Documented hypersensitivity; sinoatrial block; second- and third-degree AV block; Adams-Stokes syndrome

Precautions

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Death from cardiac arrest has occurred after too-rapid IV administration, preceded sometimes by marked QRS widening
Blood dyscrasias have occurred and thus blood counts and urinalyses should be performed when therapy is begun and at monthly intervals for several months thereafter; discontinue use if skin rash appears—if rash is exfoliative, bullous, or purpuric do not resume use; administer cautiously to patients with acute intermittent porphyria; exercise caution when administering to patients with diabetes—may raise blood glucose levels; discontinue drug if hepatic dysfunction occurs

Topiramate (Topamax)

Sulfamate-substituted monosaccharide with broad spectrum of antiepileptic activity that may have state-dependent sodium channel blocking action, potentiates inhibitory activity of neurotransmitter GABA. May block glutamate activity.

Dosing

Adult

Pediatric

Initial starting dose: 1 -3 mg/kg/d PO; increment of 1-3 mg/kg q3-4d
Maintenance dose: up to 9 mg/kg/day though 20 mg/kg/day is used for infantile spasms

Interactions

Phenytoin, carbamazepine, and valproic acid can significantly decrease topiramate levels; topiramate reduces digoxin and norethindrone levels when administered concomitantly; concomitant use with carbonic anhydrase inhibitors may increase risk of renal stone formation and should be avoided; use topiramate with extreme caution when administering concurrently with CNS depressants since may have an additive effect in CNS depression as well as other cognitive or neuropsychiatric adverse events

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Risk of developing a kidney stone formation is increased 2-4 times that of untreated population; risk may be reduced by increasing fluid intake; caution in renal or hepatic impairment; patients taking topiramate should seek immediate medical attention if they experience blurred vision or periorbital pain; continued usage after symptoms develop can lead to glaucoma; primary treatment is discontinuation of topiramate; if left untreated, serious sequelae, including permanent vision loss, may occur; oligohidrosis and hyperthermia have been reported predominantly in children during vigorous exercise or exposure to warm environmental temperatures (ensure proper hydration prior and during activity and warm temperatures)
May cause hyperchloremic, nonanion gap metabolic acidosis acute or chronic metabolic acidosis resulting in hyperventilation and nonspecific symptoms, such as fatigue and anorexia, or more severe adverse effects including cardiac arrhythmias or stupor; chronic, untreated metabolic acidosis may increase nephrolithiasis or nephrocalcinosis risk, osteomalacia (ie, rickets in pediatric patients), or osteoporosis with an increased risk for bone fractures; chronic metabolic acidosis in pediatric patients may also reduce growth rates; measure baseline and periodic serum bicarbonate level

Follow-up

Further Inpatient Care

• Patients should be observed in the inpatient unit until the physician is satisfied that the patient's condition is stabilized and that the infant is feeding well and is free of seizures that compromise feeding or sleeping. In some situations, patients may be seizure free at discharge, but this is not a requirement. Exclude reasonable alternative diagnoses prior to discharge.
• The choice to continue or discontinue any medications started can be tailored to each patient. Consider each of the following:
  • Have the seizures abated to the point that they are no longer interfering with function?
  • What is the family's level of comfort? Fully inform the patient's family of the situation and address their questions and concerns prior to discharge.
  • Is the EEG improved? A normal EEG is not required, but improvement in the EEG indicates that the diagnosis is more likely to be benign and that the prognosis is good for continued improvement at home. Likewise, the typical pattern (ie, theta pointu altérnant) indicates a benign course. Conversely, deterioration of the EEG background or development of a less benign pattern may indicate a less benign prognosis.

Further Outpatient Care

• Follow-up care should consist of one visit soon after discharge to confirm that the patient is physically and neurologically healthy. Perform a repeat EEG at that time.
• Provide later follow-up care spaced at intervals consistent with the physician's and parents' level of comfort. In general, at least 2 serial assessments spaced several months apart should demonstrate a normal EEG, normal developmental milestones, and normal findings on neurologic examination.

Inpatient & Outpatient Medications

• No known antiepileptic medications alter the behavior of the potassium channel. Other drugs known to have an effect on potassium transporters are currently being considered for investigation. No studies have revealed any medications that have any advantage over other medications. Select medications on the basis of the following two factors:
  • Appropriateness of the drug in neonates
  • Lack of significant serious adverse effects
• Currently, the most appropriate medication for neonates that can be given in both IV and PO formulation after discharge remains phenobarbital. In the future, other medications may prove more appropriate.
• Specifically, valproate and phenytoin are less appropriate.
  • Generally, valproate in very young patients is reserved for serious conditions that do not respond to therapy with other medications, because the high risk of hepatic complications must be outweighed by the risk of the seizures themselves, a situation that normally is not under consideration in a benign condition.
  • Phenytoin is less appropriate because of unpredictable decreased absorption in the neonate when administered orally.
• The most important consideration in choosing an antiepileptic medication in these patients is to remember that the syndrome is benign. Therefore, any medication chosen should have no risk of serious adverse effects.

Complications

Patients with benign familial neonatal convulsions have an increased risk of developing seizures in later life. Depending on the study, 11-20% of patients develop epilepsy in later life. Some families examined also have demonstrated an increased risk of epilepsy in apparently unaffected siblings.

Prognosis

Overall, as the name implies, benign neonatal convulsions have an excellent prognosis and resolve without neurological sequelae.

Patient Education

• Inform families with the syndrome of the risk of affected siblings, but reassure them as to the benign nature of the syndrome.
• Also alert them to the possible development of epilepsy in later life in affected as well as apparently unaffected children.
• Furthermore, inform them that the incidence of minor neurological problems is the same as expected in the general population.
• For excellent patient education resources, visit eMedicine's Brain and Nervous System Center. Also, see eMedicine's patient education article Seizures in Children.

Miscellaneous

Medicolegal Pitfalls

• Careful attention to the differential diagnosis of neonatal seizures and appropriate workup avoids most medicolegal problems. However, benign neonatal convulsions are a retrospective diagnosis and frequently present a difficult diagnostic and treatment dilemma even to the most experienced clinicians.
• Keep the family appropriately informed at all stages of the workup, diagnosis, and treatment.

Special Concerns

Other seizure types often are intermixed in families with inherited seizure disorders. This also is observed in families with benign neonatal convulsions. Children (and apparently unaffected siblings) who have benign neonatal convulsions are at an increased risk of seizures in later life.

References

1. Quattlebaum TG. Benign familial convulsions in the neonatal period and early infancy. J Pediatr. Aug 1979;95(2):257-9. [Medline].

2. Mizrahi EM. Seizure disorders in children. Curr Opin Pediatr. Dec 1994;6(6):642-6. [Medline].

3. Plouin P. Benign idiopathic neonatal convulsions (familial and non-familial): open questions about these syndromes. Epileptic Seizures and Syndromes. 1994;193-201.

4. Pettit RE, Fenichel GM. Benign familial neonatal seizures. Arch Neurol. Jan 1980;37(1):47-8. [Medline].

5. Singh NA, Westenskow P, Charlier C, et al. KCNQ2 and KCNQ3 potassium channel genes in benign familial neonatal convulsions: expansion of the functional and mutation spectrum. Brain. Dec 2003;126:2726-37. [Medline].

6. Singh NA, Charlier C, Stauffer D, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet. Jan 1998;18(1):25-9. [Medline].

7. Plouin P. [Value of video electroencephalography in neonatology]. Arch Pediatr. May 2000;7 Suppl 2:332s-333s. [Medline].

8. Biervert C, Schroeder BC, Kubisch C, et al. A potassium channel mutation in neonatal human epilepsy. Science. Jan 16 1998;279(5349):403-6. [Medline].

9. Hirose S, Zenri F, Akiyoshi H, et al. A novel mutation of KCNQ3 (c.925T-->C) in a Japanese family with benign familial neonatal convulsions. Ann Neurol. Jun 2000;47(6):822-6. [Medline].

10. Schroeder BC, Kubisch C, Stein V, et al. Moderate loss of function of cyclic-AMP-modulated KCNQ2/KCNQ3 K+ channels causes epilepsy. Nature. Dec 17 1998;396(6712):687-90. [Medline].

11. Schwake M, Pusch M, Kharkovets T, et al. Surface expression and single channel properties of KCNQ2/KCNQ3, M-type K+ channels involved in epilepsy. J Biol Chem. May 5 2000;275(18):13343-8. [Medline].

12. Singh NA, Charlier C, Stauffer D, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet. Jan 1998;18(1):25-9. [Medline].

13. Kananura C, Biervert C, Hechenberger M, et al. The new voltage gated potassium channel KCNQ5 and neonatal convulsions. Neuroreport. Jun 26 2000;11(9):2063-7. [Medline].

14. Beck C, Moulard B, Steinlein O, et al. A nonsense mutation in the alpha4 subunit of the nicotinic acetylcholine receptor (CHRNA4) cosegregates with 20q-linked benign neonatal familial convulsions (EBNI). Neurobiol Dis. Nov 1994;1(1-2):95-9. [Medline].

15. Steinlein O, Sander T, Stoodt J, et al. Possible association of a silent polymorphism in the neuronal nicotinic acetylcholine receptor subunit alpha4 with common idiopathic generalized epilepsies. Am J Med Genet. Jul 25 1997;74(4):445-9. [Medline].

16. Lerche H, Biervert C, Alekov AK, et al. A reduced K+ current due to a novel mutation in KCNQ2 causes neonatal convulsions. Ann Neurol. Sep 1999;46(3):305-12. [Medline].

17. Zhu G, Okada M, Murakami T, et al. Dysfunction of M-channel enhances propagation of neuronal excitability in rat hippocampus monitored by multielectrode dish and microdialysis systems. Neurosci Lett. Nov 10 2000;294(1):53-7. [Medline].

18. Burgess DL. Neonatal epilepsy syndromes and GEFS+: mechanistic considerations. Epilepsia. 2005;46 Suppl 10:51-8. [Medline].

19. Lehmann-Horn F, Jurkat-Rott K. Voltage-gated ion channels and hereditary disease. Physiol Rev. Oct 1999;79(4):1317-72.

20. Mulley JC, Scheffer IE, Petrou S, et al. Channelopathies as a genetic cause of epilepsy. Curr Opin Neurol. Apr 2003;16(2):171-6. [Medline].

21. Webb R, Bobele G. 'Benign' familial neonatal convulsions. J Child Neurol. Oct 1990;5(4):295-8. [Medline].

22. Tharp BR. Neonatal seizures and syndromes. Epilepsia. 2002;43 Suppl 3:2-10. [Medline].

23. DeLorenzo RJ. The challenging genetics of epilepsy. Epilepsy Res Suppl. 1991;4:3-17. [Medline].

24. Hirose S, Mitsudome A, Okada M, et al. Genetics of idiopathic epilepsies. Epilepsia. 2005;46 Suppl 1:38-43. [Medline].

25. Ben-Ari Y, Khazipov R, Leinekugel X, et al. GABAA, NMDA and AMPA receptors: a developmentally regulated 'ménage à trois'. Trends Neurosci. Nov 1997;20(11):523-9. [Medline].

26. Dzhala VI, Talos DM, Sdrulla DA, et al. NKCC1 transporter facilitates seizures in the developing brain. Nat Med. Nov 2005;11(11):1205-13. [Medline].

27. Leinekugel X, Medina I, Khalilov I, et al. Ca2+ oscillations mediated by the synergistic excitatory actions of GABA(A) and NMDA receptors in the neonatal hippocampus. Neuron. Feb 1997;18(2):243-55. [Medline].

28. Rivera C, Voipio J, Payne JA, et al. The K+/Cl- co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. Nature. Jan 21 1999;397(6716):251-5. [Medline].

29. Miles DK, Holmes GL. Benign neonatal seizures. J Clin Neurophysiol. Jul 1990;7(3):369-79. [Medline].

30. Lewis TB, Leach RJ, Ward K, et al. Genetic heterogeneity in benign familial neonatal convulsions: identification of a new locus on chromosome 8q. Am J Hum Genet. Sep 1993;53(3):670-5. [Medline].

31. Treiman LJ. Genetics of epilepsy: an overview. Epilepsia. 1993;34 Suppl 3:S1-11. [Medline].

32. Turnbull J, Lohi H, Kearney JA, et al. Sacred disease secrets revealed: the genetics of human epilepsy. Hum Mol Genet. Sep 1 2005;14(17):2491-500. [Medline].

33. Jallon P, Latour P. Epidemiology of idiopathic generalized epilepsies. Epilepsia. 2005;46 Suppl 9:10-4. [Medline].

34. Concordance of clinical forms of epilepsy in families with several affected members. Italian League Against Epilepsy Genetic Collaborative Group. Epilepsia. Sep-Oct 1993;34(5):819-26. [Medline].

35. North KN, Storey, GNB, Henderson-Smart, D.J. Fifth day fits in the newborn. Journal of Paediatrics and Child Health,. March 2008;25(5):284-287.

36. Leppert M, Anderson VE, Quattlebaum T, et al. Benign familial neonatal convulsions linked to genetic markers on chromosome 20. Nature. Feb 16 1989;337(6208):647-8. [Medline].

37. Leppert M. Novel K+ channel genes in benign familial neonatal convulsions. Epilepsia. Aug 2000;41(8):1066-7. [Medline].

38. Lewis TB, Shevell MI, Andermann E, et al. Evidence of a third locus for benign familial convulsions. J Child Neurol. May 1996;11(3):211-4. [Medline].

39. Elmslie F, Gardiner M. Genetics of the epilepsies. Curr Opin Neurol. Apr 1995;8(2):126-9. [Medline].

40. Gardiner M. Genetics of idiopathic generalized epilepsies. Epilepsia. 2005;46 Suppl 9:15-20. [Medline].

41. Camfield PR, Dooley J, Gordon K, et al. Benign familial neonatal convulsions are epileptic. J Child Neurol. Oct 1991;6(4):340-2. [Medline].

42. Tibbles JA. Dominant benign neonatal seizures. Dev Med Child Neurol. Oct 1980;22(5):664-7. [Medline].

43. Vigevano F. Benign familial infantile seizures. Brain Dev. Apr 2005;27(3):172-7. [Medline].

44. Delgado-Escueta AV, Serratosa JM, Liu A, et al. Progress in mapping human epilepsy genes. Epilepsia. 1994;35 Suppl 1:S29-40. [Medline].

Keywords

benign neonatal convulsions, second day seizures, benign neonatal seizures, benign familial neonatal convulsions, benign idiopathic neonatal convulsions, benign familial neonatal seizures, benign idiopathic neonatal seizures, fifth day disease, fifth day fits, seizure epilepsy treatment, symptoms, BFNC, BINC

Contributor Information and Disclosures

Author

Nancy Theresa Rodgers-Neame, MD, Assistant Professor, Department of Molecular Pharmacology and Physiology, University of South Florida; Director, Florida Comprehensive Epilepsy and Seizure Disorders Program
Nancy Theresa Rodgers-Neame, MD is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society, American Medical Women's Association, Society for Neuroscience, Southern Clinical Neurological Society, and Southern Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Robert Baumann, MD, Program Director, Professor, Departments of Neurology and Pediatrics, University of Kentucky
Robert Baumann, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, American College of Epidemiology, American Epilepsy Society, and Child Neurology Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Kenneth J Mack, MD, PhD, Senior Associate Consultant, Department of Child and Adolescent Neurology, Mayo Clinic
Kenneth J Mack, MD, PhD is a member of the following medical societies: American Academy of Neurology, Child Neurology Society, Phi Beta Kappa, and Society for Neuroscience
Disclosure: Nothing to disclose.

CME Editor

Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital
Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Amy Kao, MD, Assistant Professor, Department of Pediatrics, Division of Pediatric Neurology, Department of Neurology, Oregon Health and Science University; Consulting Staff, Shriners Hospital for Children
Amy Kao, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, American Epilepsy Society, and Child Neurology Society
Disclosure: Nothing to disclose.

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)